Spots Global Cancer Trial Database for erlotinib (tarceva)
Every month we try and update this database with for erlotinib (tarceva) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma | NCT00903292 | Non-Small Cell ... | erlotinib (Tarc... pemetrexed (Ali... | 20 Years - 80 Years | National Cheng-Kung University Hospital | |
| Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC) | NCT00955149 | Primary Scleros... Trisomy 7 Cholangiocarcin... Chemoprevention | Erlotinib (Tarc... | 18 Years - | Mayo Clinic | |
| A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer. | NCT00605722 | Liver Cancer | bevacizumab (Av... erlotinib (Tarc... | 18 Years - | Hoffmann-La Roche | |
| Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy | NCT00148772 | Prostate Cancer | Erlotinib (Tarc... | 18 Years - | NorthShore University HealthSystem | |
| Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma | NCT00901901 | Carcinoma, Hepa... | Sorafenib (Nexa... Erlotinib (Tarc... Placebo | 18 Years - | Bayer | |
| Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC) | NCT00153803 | Carcinoma, Non-... Non-small Cell ... NSCLC | Erlotinib (tarc... Placebo | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy | NCT00148772 | Prostate Cancer | Erlotinib (Tarc... | 18 Years - | NorthShore University HealthSystem | |
| Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- Tarceva | NCT00598156 | Metastatic Colo... | erlotinib (Tarc... bevacizumab (Av... | 18 Years - | Lund University Hospital | |
| A Phase 2 Study of Tarceva for Untreated, Good Prognosis Patients With Advanced Non-Small Cell Lung Cancer | NCT00585533 | Lung Cancer | Erlotinib (Tarc... | 18 Years - | University of Utah | |
| A Phase 2 Study of Tarceva for Untreated, Good Prognosis Patients With Advanced Non-Small Cell Lung Cancer | NCT00585533 | Lung Cancer | Erlotinib (Tarc... | 18 Years - | University of Utah | |
| Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC) | NCT00955149 | Primary Scleros... Trisomy 7 Cholangiocarcin... Chemoprevention | Erlotinib (Tarc... | 18 Years - | Mayo Clinic | |
| A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer. | NCT00605722 | Liver Cancer | bevacizumab (Av... erlotinib (Tarc... | 18 Years - | Hoffmann-La Roche | |
| Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC) | NCT00153803 | Carcinoma, Non-... Non-small Cell ... NSCLC | Erlotinib (tarc... Placebo | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA) | NCT00304278 | Head and Neck C... | Erlotinib (Tarc... Intra-arterial ... Radiation Thera... | 18 Years - | Southern Illinois University | |
| Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma | NCT00901901 | Carcinoma, Hepa... | Sorafenib (Nexa... Erlotinib (Tarc... Placebo | 18 Years - | Bayer |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
